Abbott Laboratories

Q2 FY2026 EarningsQ2 FY26 net sales of $12.59B beat consensus of $12.52B, driven primarily by the integration of Exact Sciences and high single-digit organic growth in Medical Devices and Established Pharmaceuticals. However, GAAP EPS of $0.53 missed the consensus mean of $0.95 significantly due to $0.5B in acquisition-related transaction expenses and $0.3B in stock-based compensation settlements. While the Diagnostic segment outperformed with a 42.3% YoY revenue surge, Nutritional Products underperformed expectations with a 3.1% decline in sales.